1. Effects of statin therapy on cerebrovascular and renal outcomes in patients with predialysis advanced chronic kidney disease and dyslipidemia 
Chang-Min Chung, MD, Ming-Shyan Lin, MD, Jen-Te Hsu, MD, Ju-Feng Hsiao, MD, Shih-Tai Chang, MD, Kuo-Li Pan, MD, Chun-Liang Lin, MD, Yu-Sheng Lin, MD 
Journal of Clinical Lipidology 
Volume 11, Issue 2, Pages e2 (March 2017)
DOI: /j.jacl
Copyright © 2016 National Lipid Association Terms and Conditions

2. Journal of Clinical Lipidology 2017 11, 422-431. e2DOI: (10. 1016/j
Journal of Clinical Lipidology  , e2DOI: ( /j.jacl )
Copyright © 2016 National Lipid Association Terms and Conditions

3. Figure 1
Flowchart of the study design. CKD, chronic kidney disease; ESA, erythropoietin-stimulating agent.
Journal of Clinical Lipidology  , e2DOI: ( /j.jacl )
Copyright © 2016 National Lipid Association Terms and Conditions

4. Figure 2
Kaplan–Meier curves for all-cause mortality and renal outcomes in the statin and nonstatin groups. (A)The cumulative incidence of all-cause mortality. (B) The cumulative incidence of dialysis. The inset shows the same data on an enlarged x-axis.
Journal of Clinical Lipidology  , e2DOI: ( /j.jacl )
Copyright © 2016 National Lipid Association Terms and Conditions

5. Figure 3
The incidence of all-cause mortality grouped according to different baseline data. The baseline characteristics included age, sex, diabetes mellitus, hypertension, congestive heart failure, ischemic heart failure, history of myocardial infarction, and stroke.
Journal of Clinical Lipidology  , e2DOI: ( /j.jacl )
Copyright © 2016 National Lipid Association Terms and Conditions